ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
Hematopoietic stem and progenitor cells (HSPC) are used for transplantation in patients
undergoing high dose therapy for the treatment of a range of cancers.
- HSPC are collected from the bloodstream after treatment with medications that cause the
HSPC to move from the bone marrow into the bloodstream, a process called mobilization
- between 5 and 60% of patients can fail to collect enough HSPC for a transplant, using
current mobilization techniques
- this study aims to assess the safety of combining a derivative of vitamin A, ATRA with
G-CSF (the drug most commonly used to mobilize HSPC)
- ATRA has never been combined with G-CSF for mobilization of HSPC and therefore a study
is needed to assess the safety of this combination, and whether it successfully
mobilizes HSPC